Parkinson's disease - Pipeline Insight, 2024

This “Parkinson’s disease - Pipeline Insight, 2024,”report provides comprehensive insights about 140+ companies and 150+ pipeline drugs in Parkinson’s disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Parkinson’s disease Understanding

Parkinson’s disease: Overview

Parkinson’s disease is a progressive disorder that is caused by degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. These nerve cells die or become impaired, losing the ability to produce an important chemical called dopamine. Studies have shown that symptoms of Parkinson's develop in patients with an 80 percent or greater loss of dopamine-producing cells in the substantia nigra. Normally, dopamine operates in a delicate balance with other neurotransmitters to help coordinate the millions of nerve and muscle cells involved in movement. Without enough dopamine, this balance is disrupted, resulting in tremor (trembling in the hands, arms, legs and jaw); rigidity (stiffness of the limbs); slowness of movement; and impaired balance and coordination - the hallmark symptoms of Parkinson's. The cause of Parkinson's essentially remains unknown. However, theories involving oxidative damage, environmental toxins, and genetic factors and accelerated aging have been discussed as potential causes for the disease. In 2005, researchers discovered a single mutation in a Parkinson’s disease gene (first identified in 1997), which is believed responsible for five percent of inherited cases. The majority of Parkinson's patients are treated with medications to relieve the symptoms of the disease. These medications work by stimulating the remaining cells in the substantia nigra to produce more dopamine (levodopa medications) or by inhibiting some of the acetylcholine that is produced (anticholinergic medications), therefore restoring the balance between the chemicals in the brain.

Parkinson's disease symptoms can be different for everyone. Early symptoms may be mild and go unnoticed. The symptoms may include tremor, slowed movement, known as bradykinesia, rigid muscles, impaired posture and balance, loss of automatic movements, speech changes, writing changes The diagnosis of Parkinson's is based on medical history, a review of symptoms, and a neurological and physical exam. A specific single-photon emission computerized tomography (SPECT) scan called a dopamine transporter (DAT) scan. Imaging tests - such as an MRI, ultrasound of the brain and PET scans - also may be used to help rule out other disorders. Parkinson's disease can't be cured, but medicines can help control the symptoms, often dramatically medicines may help manage problems with walking, movement and tremor. These medicines increase or substitute for dopamine. The medicines used are dopamine agonists, Monoamine oxidase B (MAO B) inhibitors, Catechol O-methyltransferase (COMT) inhibitors, Anticholinergics, adenosine receptor antagonists (A2A receptor antagonists). MRI-guided focused ultrasound (MRg FUS) is a minimally invasive treatment that has helped some people with Parkinson's disease managetremor.

Parkinson’s disease - Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Parkinson’s disease pipeline landscape is provided which includes the disease overview and Parkinson’s disease treatment guidelines. The assessment part of the report embraces, in depth Parkinson’s disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Parkinson’s disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Parkinson’s disease R&D. The therapies under development are focused on novel approaches to treat/improve Parkinson’s disease.

Parkinson’s disease Emerging Drugs Chapters

This segment of the Parkinson’s disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Parkinson’s disease Emerging Drugs

Tavapadon: Cerevel Therapeutics Tavapadon is an orally-bioavailable, once-daily partial agonist that selectively targets dopamine D1/D5 receptor subtypes. The drug is designed to improve motor symptoms by selectively targeting and binding to dopamine D1/D5 receptor subtypes and to activate the D1/D5 receptor subtypes at levels that maximize motor benefit while reducing the prolonged receptor over excitation and desensitization caused by full agonists, which can lead to dyskinesia’s and exacerbation of “off” time. Currently it is in Phase III stage of clinical trial evaluation to treat Parkinson’s disease.

IkT-148009: Inhibikase Therapeutics IkT-148009 is a potent, selective small-molecule, oral medication targeting the underlying biological mechanism with the goal of halting disease progression and reversing functional loss. The drug is designed to block the activation of Abl kinase, a clinically validated drug target, to halt and reverse the loss of dopamine-secreting neurons in the brain and GI tract by restoring neuroprotective mechanisms. IkT-148009 is currently being evaluated in the Phase II studies for the treatment of Parkinson’s disease.

NLY01 : Neuraly NLY01 is a first-in-Class GLP-1R agonist for Neurodegenerative Disease. It is a pegylated exendin-4 analogue of glucagon like peptide-1 receptor (GLP-1R) agonist. NLY01 penetrates the blood-brain barrier (BBB) and its receptor (GLP-1R) is highly expressed on glial cells. Currently the drug is being evaluated in Phase II for the treatment of Parkinson’sdisease.

PT320: Peptron PT320 (Exenatide) is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) belonging to the group of incretin mimetics. It is a synthetic version of exendin-4, a hormone found in the saliva of the Gila monster, and it is a 39-amino-acid peptide, inducing insulin secretion. Exenatide binds to the intact human GLP-1 receptor in a similar way to the human GLP-1. Currently the drug is being evaluated in Phase II for the treatment of Parkinson’sdisease.

BIIB094: Biogen BIIB094, also known as ION859 is an investigational antisense medicine designed to inhibit the production of the leucine-rich repeat kinase 2 (LRRK2) protein as a potential therapy. It binds the m RNA for leucine-rich repeat kinase 2 and mediates its degradation. This results in lower LRRK2 protein levels. Currently the drug is being evaluated in Phase II for the treatment ofParkinson’sdisease.

Parkinson’s disease: Therapeutic Assessment

This segment of the report provides insights about the different Parkinson’s disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Parkinson’s disease

There are approx. 140+ key companies which are developing the therapies for Parkinson’s disease. The companies which have their Parkinson’s disease drug candidates in the most advanced stage, i.e. phase III include, Cerevel Therapeutics

Phases

This report covers around 150+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Parkinson’s disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Parkinson’s disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Parkinson’s disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Parkinson’s disease drugs.

Parkinson’s disease Report Insights

• Parkinson’s disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Parkinson’s disease Rep ort Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Parkinson’s disease drugs?
• How many Parkinson’s disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Parkinson’s disease?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Parkinson’s disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Parkinson’s disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Cerevel Therapeutics
• Inhibikase Therapeutics
• Neuraly
• Peptron
• Biogen
• Prevail Therapeutics
• Luye Pharma Group Ltd
• FAScinate Therapeutics Inc.
• Neurocrine Biosciences
• Sangamo Therapeutics
• AstraZeneca
• Hoffmann-La Roche
• Brain Neurotherapy Bio, Inc
• Annovis Bio Inc
• Anavex Life Sciences Corp
• Alexza Pharmaceuticals, Inc.
• Pharma Two B Ltd.
• Meira GTx,LLC
• BioVie Inc.
• Takeda Pharmaceuticals

Key Products

• Tavapadon
• IkT-148009
• NLY01
• PT320
• BIIB094
• LY3884961
• LY03003
• KM-819
• VY-AADC02
• CERE-120
• MEDI1341
• RO7046015
• AAV2-GDNF
• Posiphen
• ANAVEX2-73
• CERE-120
• Apomorphine Cartridge
• P2B001
• AAV-GAD
• NE3107
• TVP-1012

This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.